Key Slides: AASLD Guidance on Evaluating Liver Fibrosis and Inflammation in Hepatitis B Infection

Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.
Anna Christina L. dela Cruz, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.27 MB
Released: April 20, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Clinical Care Options (CCO) commentary from Maria Buti, MD, on the interplay between HBV infection and pregnancy

Maria Buti, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 18, 2022 Expired: April 17, 2023

Clinical Care Options (CCO) commentary by Dr. Kenneth Sherman discussing underuse of HBV vaccines in adults and the role of new vaccine formulations

Kenneth E. Sherman, MD, PhD Released: April 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings